Medical Necessity Criteria for IVF: What Payers Actually Require

Medical necessity for IVF is one of the most misunderstood concepts in fertility billing — not because the concept is complicated, but because "medical necessity" means something entirely different at each payer, and the criteria change when policy bulletins are updated without notice to providers. A practice that successfully obtained IVF authorization for a patient with unexplained infertility in 2024 may find the same clinical profile denied in 2026 because the payer updated its step-therapy requirements, changed the minimum duration of infertility, or revised the number of required failed IUI cycles. Understanding what each major payer actually requires — not what the front desk assumes based on a prior approval, not what the payer representative said over the phone, but what the current written clinical policy specifies — is the foundational competency of IVF prior authorization.

This guide covers the specific medical necessity criteria applied by the four largest commercial payers — Aetna, United Healthcare, Cigna, and Blue Cross Blue Shield state plans — as well as the documentation standards practices must meet to satisfy those criteria on initial authorization requests. The CPT codes principally at issue are 58970 (follicle puncture for oocyte retrieval), 58974 (embryo transfer), and the embryology laboratory codes 89250 through 89281. Authorization is typically required for all of these codes as a bundled service package, and a deficiency in the medical necessity documentation for any component of the IVF cycle can produce a denial of the entire authorization request.

Why IVF Medical Necessity Is Not a Single Universal Standard

Unlike most specialty services, where payer medical necessity criteria converge around USPSTF guidelines, specialty society recommendations, or FDA-approved indications, IVF medical necessity criteria diverge substantially across payers. Each major commercial carrier publishes its own clinical policy bulletin or coverage determination guideline, and those documents are binding on the payer's clinical review staff regardless of what ASRM guidelines recommend, what the treating REI physician recommends, or what neighboring states require by mandate. A patient with N97.9 (unexplained infertility) and a 14-month history of unprotected intercourse without conception may qualify for IVF authorization at Aetna after three failed IUI cycles but require six at Cigna, or may be denied at a BCBS plan that does not cover IVF at all under the employer's self-funded plan design.

The practice's job in prior authorization is not to argue that IVF is medically appropriate — every REI physician already believes that. The job is to demonstrate that the specific patient meets the specific criteria in the specific version of the specific payer's clinical policy that governs coverage for the specific plan. Those five "specifics" define the submission. A submission that satisfies four out of five will be denied. Understanding each payer's criteria in detail, verifying that the current policy version is the one being applied to the authorization request, and documenting each criterion as a discrete checklist item before submitting the authorization is the process that produces first-pass approval rates above 80%.

The Core Elements of IVF Medical Necessity Criteria Across All Major Payers

Despite the variation across payers, IVF medical necessity criteria share a common structural framework at every major commercial carrier. Every payer's clinical policy for IVF contains some version of the following four elements, with the specific thresholds and requirements varying by payer.

• Infertility diagnosis: the patient must carry a documented ICD-10 diagnosis code for infertility or a condition causally related to infertility. Encounter codes (Z31.83 — encounter for assisted reproductive technology), history codes, and Z-codes for fertility counseling are not accepted as the primary diagnosis for IVF authorization. The underlying clinical diagnosis — N97.0 (female infertility due to anovulation), N97.1 (tubal factor), N97.2 (uterine factor), N97.4 (associated with male factor), N97.8 (other specified cause), N97.9 (unexplained) — must be the code submitted on the authorization request and must be supported by diagnostic evidence in the clinical record.
• Duration of infertility: most payer policies require documentation of a minimum duration of infertility before IVF is covered. The standard threshold is 12 months of unprotected, appropriately timed intercourse without conception for patients under 35, and 6 months for patients 35 to 37 years old. Most policies are silent on a duration requirement for patients 38 and older, implicitly recognizing that age-related decline in ovarian reserve makes waiting clinically inappropriate. Duration must be documented in the clinical history, not merely asserted in the authorization narrative.
• Step-therapy requirements: the most commonly litigated element of IVF medical necessity criteria. Most payers require documentation that less invasive treatments were attempted and failed before IVF is covered for diagnoses where those treatments are clinically applicable. For ovulatory dysfunction (N97.0), step therapy typically requires 3 to 6 cycles of ovarian stimulation with IUI. For unexplained infertility (N97.9), requirements range from 3 IUI cycles at Aetna and UHC to 6 IUI cycles at Cigna and some BCBS plans. For diagnoses where IUI is clinically contraindicated, step-therapy requirements are waived — but the clinical basis for the waiver must be explicitly documented in the authorization submission.
• Exclusion criteria: payer policies include conditions under which IVF is specifically not covered regardless of the infertility diagnosis. Common exclusions include prior failed IVF cycles exceeding the payer's lifetime maximum (typically 3 to 6 cycles, depending on state mandate requirements); absence of a viable uterus in a patient not using a gestational carrier; male partner with azoospermia where no surgical sperm retrieval option is viable; and patient age above the payer's coverage ceiling, which ranges from 42 to 45 years of age for fresh cycle coverage across major commercial carriers.

Major Payer IVF Medical Necessity Criteria: A Policy-by-Policy Reference

IVF Bypass Diagnoses: When Step Therapy Is Not Required

The IUI step-therapy requirement is the most common source of IVF medical necessity denials — not because the requirement is invalid, but because practices either fail to document completed IUI cycles correctly or fail to recognize that the patient's diagnosis entitles them to bypass the requirement entirely. Every major payer's IVF clinical policy contains a list of diagnoses for which IVF is covered as first-line treatment without requiring prior IUI attempts. These bypass diagnoses recognize clinical situations where IUI is not physiologically viable, not clinically appropriate, or would expose the patient to material harm through delay. Understanding which diagnoses carry the bypass is essential to submitting authorizations correctly for patients who should not be required to fail through IUI before obtaining IVF coverage.

• N97.1 — Female infertility due to tubal factor (bilateral tubal occlusion, bilateral hydrosalpinges, or combined tubo-peritoneal disease): IUI requires functional fallopian tubes for sperm transport; bilateral tubal occlusion makes IUI anatomically non-contributory. Required documentation: HSG report documenting bilateral non-patency, or operative laparoscopy note documenting bilateral occlusion, hydrosalpinges, or extensive peritubal adhesive disease. Unilateral occlusion with a normal contralateral tube does not automatically qualify for bypass at all payers — verify the payer-specific policy language, as Aetna CPB 0327 specifies bilateral occlusion or a single patent tube with the contralateral tube significantly compromised.
• N46.021 / N46.121 — Male infertility due to azoospermia (obstructive or non-obstructive): zero sperm in the ejaculate makes conventional IUI impossible; IVF with ICSI using surgically retrieved sperm is the only viable pathway. Required documentation: minimum two semen analyses per WHO 6th Edition 2021 criteria confirming azoospermia, urologist consultation confirming the azoospermia etiology and retrieval candidacy, and the surgical retrieval plan (TESE: CPT 54500; microsurgical epididymal sperm aspiration: CPT 54505 or carrier-specific code). ICSI is billed separately under CPT 89280 (intracytoplasmic sperm injection, less than or equal to 5 oocytes) or 89281 (more than 5 oocytes).
• E28.310 — Premature ovarian insufficiency (symptomatic premature menopause / primary ovarian failure): serum FSH above 40 mIU/mL and estradiol below 20 pg/mL in a patient under 40 confirm ovarian failure; ovarian stimulation for IUI is not physiologically viable when the ovaries are non-functional. Required documentation: serum FSH and estradiol drawn on cycle day 2 or 3 with numeric values, reference ranges, lab name, and collection date. This is the strongest bypass position in fertility billing — no major payer requires IUI step-through before IVF when ovarian failure is confirmed.
• E28.39 with AMH below 1.0 ng/mL or AFC below 5–7 — Diminished ovarian reserve (other primary ovarian failure): recognized at Aetna (CPB 0327) and UHC (CDG CS-0037.D) as a direct IVF indication; delaying IVF to complete multiple IUI cycles would further deplete already limited ovarian reserve. Required documentation: AMH serum level with numeric value from a quantitative assay (not a qualitative "low/normal" result), AFC from transvaginal ultrasound on cycle day 2–3 with specific follicle count. Narrative AMH descriptions without a numeric value will not satisfy the documentation requirement at any payer.
• N96 — Recurrent pregnancy loss with 2 or more documented losses (Cigna) or 3 or more documented losses (most other payers): RPL with chromosomal etiology supports IVF with PGT-A (billed under 81479 or carrier-specific genetic testing code) to screen embryos prior to transfer; the clinical rationale is that ongoing unscreened transfer perpetuates a cycle of pregnancy loss that PGT-A can interrupt. Required documentation: prior pregnancy records confirming each loss with gestational age, beta hCG trend, and karyotype or chromosomal microarray of products of conception if performed.
• N80.3 / N80.4 — Endometriosis Stage III or IV with documented tubo-ovarian involvement: extensive endometriosis with adhesive disease, bilateral endometriomas, or peritubal scarring produces mechanical tubal compromise and inflammatory ovarian toxicity that makes IUI clinically ineffective. Required documentation: operative laparoscopy report with ASRM endometriosis staging notation and documentation of anatomic findings specifically describing tubal involvement, adhesive disease extent, and endometrioma characteristics; pathology report confirming endometrial implants if tissue was biopsied.
• N97.4 with total motile count below 5 million (on WHO 6th Edition semen analysis) — Female infertility associated with severe male factor: IUI success rates fall below 5–8% per cycle when the prepared total motile sperm count is below 5 million; most payer policies recognize this as the clinical boundary where IUI is not appropriate. Required documentation: semen analysis report dated within 12 months of the authorization, with total sperm count, progressive motility percentage, morphology (Kruger strict criteria), and the explicitly calculated total motile count. The calculation must be stated in the documentation — payer reviewers will not perform it independently.

Documentation Required to Satisfy Medical Necessity on Initial Authorization

IVF prior authorizations are denied on initial submission more often because of documentation deficiencies than because the patient clinically fails to qualify. Authorization reviewers are administrative staff working from a criterion checklist — they are not clinicians making independent clinical judgments. If the checklist item for three documented failed IUI cycles requires a cycle summary report and the practice submits only a narrative attestation letter, the criterion is unchecked and the authorization is denied regardless of how thorough the physician's clinical notes are. Meeting the clinical criteria is necessary but not sufficient — documenting each criterion in the format the payer's reviewer can check off is what produces first-pass approvals.

• Infertility diagnosis with supporting diagnostic evidence: submit the applicable ICD-10 code and the diagnostic test or clinical finding that confirms it — HSG report for tubal factor, semen analysis for male factor, serum FSH and E2 for POI, AMH and AFC for DOR, ovulation tracking records for anovulatory N97.0, and laparoscopy report for endometriosis. The code alone is insufficient; the evidence that establishes the diagnosis must accompany the authorization submission.
• Duration of infertility: a dated clinical note from the first visit documenting the patient's reported history of unprotected intercourse without conception, with specific months counted and the date the patient first presented for infertility evaluation. Many practices use a structured infertility history intake form that captures this information at the first visit — submit a copy or an excerpt from the intake note dated from the initial consultation.
• Failed IUI documentation: for each IUI cycle claimed as a step-therapy attempt, submit a cycle summary that includes the treating physician name and practice, cycle start date and end date, stimulation protocol (drug name, dose, and administration dates), peak estradiol and follicle count on trigger day (confirming adequate ovarian response), insemination date, total motile count inseminated, and outcome documentation (negative serum beta hCG with numeric value and date). Submit a separate cycle summary for each cycle — a cumulative narrative such as "patient completed 3 IUI cycles" will be rejected by most payers as insufficient to verify the step-therapy requirement.
• Ovarian reserve testing results: AMH serum level from a quantitative assay, antral follicle count from transvaginal ultrasound, and day 3 FSH and estradiol if obtained. All results must include numeric values, reference ranges, lab or facility name, date of collection, and interpreting provider signature or attestation. Results older than 12 months may be rejected at some payers; verify recency requirements in the current policy version.
• Current semen analysis: for any cycle where male factor is part of the clinical picture, submit the most recent semen analysis dated within 12 months using WHO 6th Edition 2021 reference values. Include collection date, abstinence interval, total sperm count, progressive motility percentage, total motility percentage, morphology percentage (Kruger strict criteria), and the calculated total motile count. Note the laboratory name and whether the analysis was performed in-house or by an external andrology laboratory.
• REI physician letter of medical necessity: a signed narrative from the treating REI physician summarizing the patient's diagnosis, infertility history, prior treatments, and clinical rationale for IVF. The letter must specifically map the patient's clinical findings to the payer's criteria by name and section — a letter that argues the appropriateness of IVF in general terms without addressing each criterion in the current policy will not satisfy the requirement. For payers with well-known policies (Aetna CPB 0327, UHC CDG CS-0037.D, Cigna Policy 0527), the letter should cite the policy document by title and the specific section that supports coverage for this patient's diagnosis.
• Age and plan eligibility verification: confirm the patient's date of birth against the payer's age ceiling for fresh IVF coverage (ranges from 42 to 45 across major payers), the current plan effective date, plan type (fully insured versus self-funded — self-funded plans can contractually exclude fertility coverage regardless of state mandate requirements), and the member's remaining benefit maximum for fertility services if the plan has a cycle or dollar limit.

ICD-10 Code Selection and Its Direct Impact on Medical Necessity Outcomes

Common Medical Necessity Denial Reasons and Front-End Prevention Strategies

The most common medical necessity denials for IVF authorization are preventable on the front end — not through clinical argument on appeal, but through correct submission on first submission. The following denial patterns account for the majority of first-submission medical necessity denials at fertility practices that do not use a structured IVF authorization checklist built around current payer policy criteria.

• Insufficient IUI cycle documentation: the leading denial reason at all payers with step-therapy requirements. Each IUI cycle must be individually documented with stimulation protocol, peak stimulation response, insemination parameters, and a negative outcome result. Practices that accept only a summary letter from the patient's referring OB/GYN stating "patient completed 3 IUIs" will routinely be denied. Obtain the actual cycle records from the referring practice before submission — a narrative attestation is not a cycle summary and will not satisfy the documentation requirement at Aetna, UHC, or Cigna.
• Wrong ICD-10 code creating an unintended step-therapy requirement: submitting N97.9 (unexplained) when the patient has documented PCOS that should be coded N97.0, or using N97.0 when tubal factor (N97.1) is the actual diagnosis. Each code change may add or remove a step-therapy requirement. Have the REI physician confirm the primary diagnosis code before each authorization is submitted — not just the description, but the actual ICD-10 code — because coders may default to a familiar code without reviewing the specific patient chart.
• AMH or AFC values submitted without numeric results: payers that list E28.39 or DOR as a bypass diagnosis require the actual AMH value in ng/mL and the AFC follicle count on the authorization submission. A narrative stating "patient has diminished ovarian reserve" or "AMH is low" does not satisfy the requirement. Attach the actual lab report (with numeric value, reference range, lab name, and collection date) and the ultrasound report (with specific antral follicle count) to every DOR authorization.
• Policy version mismatch: submitting documentation designed for a 2024 policy version when the payer has since updated its IVF criteria. Practices that trained authorization staff on a prior policy and never revisited it may unknowingly be citing superseded step-therapy counts, bypassed diagnoses that no longer qualify, or diagnostic thresholds that have changed. Assign one team member to download the current policy version from each major payer's provider portal at the start of each calendar quarter.
• Physician letter of medical necessity is generic rather than criterion-specific: the REI physician's letter discusses the general appropriateness of IVF without addressing each of the payer's specific criteria. Build a payer-specific letter template for each major payer that prompts the physician to state the patient's diagnosis, duration of infertility, prior IUI cycle outcomes, relevant test results, and the specific policy section that supports coverage for this patient. A criterion-specific letter takes no longer to complete with a template and produces measurably higher first-pass approval rates.
• Authorization submitted only for retrieval, not for the full cycle: some practices submit authorization only for CPT 58970 (oocyte retrieval) and then discover that the payer also requires separate authorization for 58974 (embryo transfer) and the embryology laboratory codes (89250–89281). Build a payer-specific CPT code authorization checklist that identifies which codes require prior authorization at each payer, and submit authorization for all required codes simultaneously at the start of each IVF cycle rather than sequentially as services approach.

Self-Funded Plans and the ERISA Preemption Problem

State fertility insurance mandates govern fully insured health plans — plans where the employer pays premiums to the insurance carrier and the carrier bears the financial risk of claims. They do not apply to self-funded (ERISA) plans, where the employer bears the financial risk of claims and uses the insurance carrier only as a third-party claims administrator. The majority of large employer group health plans are self-funded, and self-funded plans are permitted under ERISA to exclude fertility coverage entirely, cap IVF benefits below state mandate levels, or impose stricter medical necessity criteria than those in the carrier's standard clinical policy bulletin. A United Healthcare member employed by a large corporation with a self-funded plan may have zero IVF coverage even in a state with an unlimited IVF mandate — because the mandate only applies to the carrier's fully insured products, not the employer's self-funded plan document.

Identifying plan type before submitting an IVF authorization is not optional — it determines whether the standard payer clinical policy applies to the member at all, or whether the practice needs to request and review the employer's Summary Plan Description (SPD) to identify what fertility benefits the specific plan document provides. Plan type is available from the insurance card (self-funded plans often carry the notation "Administrative Services Only" or "ASO"), from the payer's eligibility portal under the plan type field, or by calling payer provider services and asking directly whether the specific group number is a fully insured or self-funded plan. Submitting an IVF authorization for a self-funded plan member without first verifying the specific plan's fertility benefit design frequently results in a denial that cannot be overturned on clinical appeal — because the denial is based on the plan document exclusion, not on a clinical necessity determination, and the plan document is legally controlling under ERISA regardless of the patient's clinical need.